Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07037771 · ClinicalTrials.gov registry record · Phase 3

A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)

A Phase 3 study of Homozygous Familial Hypercholesterolemia, sponsored by Arrowhead Pharmaceuticals.

Recruiting
Registry status
Phase 3
Development phase
60
Enrollment target
16
Study locations

NCT07037771 is a Phase 3 study of Homozygous Familial Hypercholesterolemia that is actively recruiting participants, run by Arrowhead Pharmaceuticals. The registered enrollment target is 60 participants, below the 242-participant average among 6 other Homozygous Familial Hypercholesterolemia trials with a reported enrollment target (75% lower). The trial reports 16 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07037771, a Phase 3 study of Homozygous Familial Hypercholesterolemia, is actively recruiting participants, sponsored by Arrowhead Pharmaceuticals.

RECRUITING
Registry status
Phase 3
Development phase
60 participants
Enrollment target
16
Study locations

Study Summary

This multicenter, randomized, placebo-controlled study will evaluate the efficacy and safety of zodasiran subcutaneous (SC) injection in subjects 12 years of age and older with genetically or clinically diagnosed Homozygous familial hypercholesterolemia (HoFH). After completion of the double blind (DB) treatment period subjects will be eligible to continue in the optional open-label extension (OLE) period of the study. All placebo subjects who opt to continue will transition to active drug during the OLE Period.

Conditions Studied

Homozygous Familial Hypercholesterolemia

Interventions

  • DRUG Placebo
  • DRUG zodasiran Injection

Study Locations (16)

Other

  • Research Site 10 - Jerusalem
  • Research Site 15 - Tel Litwinsky
  • Research Site 12 - Christchurch
  • Research Site 8 - Cape Town

New South Wales

  • Research Site 13 - Camperdown
  • Research Site 9 - Saint Leonards

Quebec

  • Research Site 6 - Chicoutimi
  • Research Site 4 - Québec

Illinois

  • Research Site 7 - Park Ridge

New York

  • Research Site 2 - New York

Ohio

  • Research Site 1 - Cincinnati

Pennsylvania

  • Research Site 14 - Pittsburgh

Western Australia

  • Research Site 3 - Nedlands

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-06-17
Est. Completion 2027-08-20
Phase Phase 3

Sponsor

Arrowhead Pharmaceuticals

15 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07037771

The ClinicalTrials.gov registry entry for NCT07037771 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 6 other Homozygous Familial Hypercholesterolemia trials with a reported enrollment target (75% lower). The listed sponsor is Arrowhead Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Homozygous Familial Hypercholesterolemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07037771 reports 16 study locations spanning 11 distinct geographic areas - top geographies include Other, New South Wales, Quebec.

Frequently Asked Questions

What is clinical trial NCT07037771 about?

NCT07037771 is a clinical study titled "A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)". This multicenter, randomized, placebo-controlled study will evaluate the efficacy and safety of zodasiran subcutaneous (SC) injection in subjects 12 years of age and older with genetically or clinically diagnosed Homozygous familial hypercholesterolemia (HoFH). After completion of the double blind (...

What is the current status of trial NCT07037771?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2025-06-17. Estimated completion is 2027-08-20.

What conditions does trial NCT07037771 study?

This clinical trial studies the following conditions: Homozygous Familial Hypercholesterolemia.

What interventions are being tested in trial NCT07037771?

The interventions under investigation include: Placebo (DRUG), zodasiran Injection (DRUG).

Who is sponsoring clinical trial NCT07037771?

This trial is sponsored by Arrowhead Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07037771 being conducted?

This trial has 16 study locations across Illinois, New York, Ohio, Pennsylvania, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Homozygous Familial Hypercholesterolemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Homozygous Familial Hypercholesterolemia

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.